| Evaluation of Pre-Exposure Prophylaxis Against HIV in Alpine Region (NCT03995862) | Centre Hospitalier Annecy Genevois | 2019-05-29 |
| Linkage of Transgender Individuals to PrEP (NCT03191474) | University of California, San Diego | 2017-07-28 |
| Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (NCT03086200) | University of California, San Diego | 2017-06-23 |
| Pre-exposure Prophylaxis Accessibility Research and Evaluation 2 (NCT02125773) | University of California, San Diego | 2014-02-19 |
| CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM (NCT01761643) | University of California, San Diego | 2012-12-19 |
| Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults (NCT01418235) | HIV Vaccine Trials Network | 2011-12-19 |
| Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials (NCT00789789) | ANRS, Emerging Infectious Diseases | 2008-12-01 |
| Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm (NCT00076817) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-06-01 |
| A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes (NCT00076232) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-04-01 |
| Safety of Intradermal Versus Intramuscular Administration of HIV Lipopeptides in HIV Uninfected Adult Volunteers (NCT00121121) | French National Agency for Research on AIDS and Viral Hepatitis | 2004-07-01 |
| Botanical/Drug Interactions in HIV: Glucuronidation (NCT00065741) | National Center for Complementary and Integrative Health (NCCIH) | 2003-09-01 |
| Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients (NCT00055237) | National Cancer Institute (NCI) | 2003-02-26 |
| HIV Incidence and Participation Retention in Pune, India (NCT00028119) | HIV Prevention Trials Network | 2002-08-01 |
| Screening Protocol for HIV Vaccine Studies (NCT00031304) | National Institute of Allergy and Infectious Diseases (NIAID) | 2002-02-27 |
| Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand (NCT00006327) | VaxGen | 1999-03-01 |
| A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection (NCT00004579) | Walter Reed Army Institute of Research (WRAIR) | 1998-04-01 |
| The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs (NCT00017758) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of GENEVAX-HIV, a Possible Vaccine (NCT00002232) | Wyeth-Lederle Vaccines | |
| A Study to Test the Safety of Three Experimental HIV Vaccines (NCT00000946) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia (NCT00078182) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Immune System Activity in Healthy Adults (NCT00014053) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection (NCT00002441) | VaxGen | |
| A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 (NCT00000972) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers (NCT00000879) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| ALVAC-HIV vCP1452 Alone and Combined With MN rgp120 (NCT00011037) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Carotid Artery Thickness in HIV Infected and Uninfected Adults (NCT00007319) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa (NCT00006298) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women (NCT00000809) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo) (NCT00000777) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I, Observer-Blind, Placebo-Controlled Study of the Chiron Vaccine HIV p24/MF59 Administered to Healthy HIV-Seronegative Adults (NCT00002204) | Chiron Corporation | |
| A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers (NCT00000868) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Male Rectal Samples in Preparation for Future Rectal Microbicide Trials (NCT00075062) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Active Immunization of HIV-Infected Pregnant Women: A Phase I Study of Safety and Immunogenicity of a rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo) (NCT00001046) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults (NCT00027261) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine (NCT00001136) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59 (NCT00000632) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules (NCT00001043) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Blood Test to Look at Cells of the Immune System in Healthy Children (NCT00001109) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers (NCT00000774) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission (NCT00053612) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| HIV Prevention Preparedness Study (NCT00048282) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults (NCT00013572) | Walter Reed Army Institute of Research (WRAIR) | |
| Long-Term Effects of HIV Exposure and Infection in Children (NCT00006304) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru (NCT00023582) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers (NCT00002231) | Wyeth-Lederle Vaccines | |